Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986453 in Newly Diagnosed Multiple Myeloma
NCT07333261Phase 1Active, not recruiting
- Sponsor
- Susan Bal
- Start
- Feb 2026
- Primary completion
- Dec 2031
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BMS-986453 in multiple myeloma (MM), sponsored by Susan Bal. Primary endpoint: Number of participants with treatment-related adverse events at 5 years. Started Feb 2026; status: active, not recruiting.
02
Drugs
BMS-986453
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07333261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07333261.